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Abstract 
Scorpion venom is a highly complex mixture of about 100–700 different components, where peptides are the major 
constituents with various biological and pharmacological properties including anticancer activities. In this study, anti‑
cancer efficacy of the venom of the Egyptian scorpion Androctonus amoreuxi has been evaluated. In vitro, the human 
breast cancer MCF‑7 cell line was treated with the venom and the IC50 was estimated. In vivo studies, Ehrlich ascites 
carcinoma (EAC) cells were inoculated into CD‑1 mice intraperitoneally to form liquid tumor or subcutaneously to 
form solid tumor and then treated with intraperitoneal injection with venom (0.22 mg/kg) every other day. The total 
tumor cells in the ascitic fluid and the size of the solid tumor were assessed after 14 and 30 days, respectively. In addi‑
tion, the mean survival time (MST), body weight, tumor volume, PCV, viability of tumor cells, CBC, AST, ALP, creatinine, 
oxidative stress biomarkers (GSH, MDA, PCC), tumor marker Ki67, growth factor VEGF and caspase‑3 were measured 
in normal control, EAC control and venom‑treated groups (n = 6). Treatment with venom induced anti‑tumor effects 
against liquid and in solid tumors as indicated by a significant (P < 0.05) reduction in tumor volume/size, count of 
viable EAC cells, expression of Ki67 and VEGF as well as by remarkable increases in MST and caspase‑3 expression 
as compared to non‑treated group. Interestingly, the venom restored the altered hematological and biochemical 
parameters of tumor‑bearing animals and significantly increased their life span. These data indicate to (1) the cyto‑
toxic potential effects of A. amoreuxi on tumor cells via anti‑proliferative, apoptotic and anti‑angiogenic activities; (2) 
opening a new avenue for further studies on the anti‑cancer effects of this agent.
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Background
According to the reports and statistics from the Inter-
national Agency for Research on Cancer (IARC) and the 
World Health Organization (WHO), cancer has become 
the leading cause of deaths worldwide (7.6, 8.2 million 
deaths in 2008 and 2012, respectively) (Jemal et al. 2011; 
Ferlay et al. 2013). However chemotherapy and radiother-
apy are extensively being used to treat several types of 
tumors, they have many disadvantages such as (1) delete-
rious side effects on normal cells (lack of specificity); (2) 
low success rate and (3) high risk of recurrence. Conse-
quently, development of new safe and effective strategies 
for cancer diagnosis and treatment is extremely needed. 
One of these alternative approaches is using anticancer 
peptides derived from animal venoms including scorpi-
ons. Various previous studies revealed effectiveness of 
the crude scorpion venoms and certain purified peptides 
(such as iberiotoxin margatoxin, charybdotoxin, AGAP-
SYPU2 and chlorotoxin) against cancer cells through dif-
ferent mechanism of actions (Deshane et al. 2003; Bloch 
et  al. 2007; Liu et  al. 2009; Jang et  al. 2011; Zhao et  al. 
2011; Shao et al. 2014; Ding et al. 2014; Ortiz et al. 2015).
Scorpion venom is a cocktail of protein (enzymes and 
peptides) and non-protein (inorganic salts, lipids, nucleo-
tides, free amino acids and water) substances produced 
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by the venom gland for defense and prey capture (Rod-
riguez de la Vega and Possani 2005; Abdel-Rahman et al. 
2015). Disulfide-bridged peptides and non-disulfide-
bridged peptides constitute the major groups of scorpion 
venom and many of them have been characterized with 
analgesic, anti-epileptic, hemolytic, anti-thrombotic, 
anti-inflammatory, antimicrobial and anticancer activi-
ties (Yu et  al. 1992; Wang et  al. 2001; Zeng et  al. 2005; 
Song et  al. 2005; Shao et  al. 2007; Mamelak 2011; Har-
rison et  al. 2014, 2016; Almaaytah and Albalas 2014; 
Abdel-Rahman et al. 2016).
The anticancer efficacy of scorpion venoms has been 
examined in various types of cancers as glioma, neuro-
blastoma, leukemia, lymphoma, breast, lung, prostate 
and pancreatic cancer (Ding et al. 2014). Only a few tox-
ins have been found to be the responsible for these anti-
cancer effects and exert their action by three different 
mechanisms: (1) blocking specific ion channels (Jager 
et  al. 2004); (2) inhibiting invasion and metastasis of 
cancer cells (Deshane et al. 2003); (3) activating intracel-
lular pathways leading to cell cycle arrest and apoptosis 
(Gupta et  al. 2010). Recently, venom from the Buthidae 
scorpions Androctonus bicolor, Androctonus crassicauda, 
and Leiurus quinquestriatus (collected from Saudi Ara-
bia) revealed strong anticancer activity on colorectal and 
breast cancer cell lines (HCT-116 and MDA-MB-231, 
respectively) through decreasing cell motility and colony 
formation of cancer cells (Al-Asmari et al. 2016).
However several scorpion species (about 24 species) 
are widespread in Egypt, only few studies highlighted 
anticancer activity of scorpion venoms such as L. quin-
questriatus (Omran 2003). The present study was con-
ducted to examine the cytotoxic activity and mechanism 
of action of the Egyptian scorpion venom A. amoreuxi 
on the Ehrlich ascites carcinoma (EAC) cells and human 
breast cancer MCF-7 cell line using both in  vitro and 
in vivo approaches.
Methods
Scorpion venom collection and preparation
About 200 specimens of A. amoreuxi scorpions were 
captured from the Western Mediterranean Costal Desert 
(Alexandria, Egypt) in August 2010. Scorpions were kept 
alive in separate plastic containers and fed with cock-
roaches and received water ad libitum. The crude venom 
was collected using electrical stimulation (12–16 V, 3 ms) 
of the scorpion telson according to the method described 
by Abdel-Rahman et al. (2013). The pooled venom (col-
lected from different scorpion specimens) was dissolved 
in distilled water and centrifuged for 10 min at 5000 rpm 
to remove cellular debris. Then, supernatant was imme-
diately freeze dried (Labconco freeze dry system, model 
77500, USA) and stored at −20 °C until use.
Experimental animals, ethics and cancer cell lines
Swiss Webster albino mice (20–25  g) were housed in 
plastic cages (ten animals/cage) under standard labo-
ratory conditions (27  ±  2  °C; 70–80  % humidity; 12-h 
light/darkness cycle) with standard pellet diet and water 
ad libitum. The animals were handled in accordance with 
current guidelines for the care of laboratory animals 
and ethical guidelines for the investigation of experi-
mental pain in conscious animals. All efforts were made 
to minimize the number of animals used and their suf-
fering. The first inoculum of EAC and MCF-7 cell lines 
was purchased from the National Cancer Institute, and 
VACSERA (Cairo, Egypt), respectively. EAC cells were 
propagated in the peritoneal cavity of mice through serial 
intraperitoneal (IP) transplantation of 106 cells (in 0.2 ml 
of PBS/animal) and transferred every 7 days to new ani-
mals. Mice were monitored daily and cell viability was 
evaluated using trypan blue dye exclusion method (Bin-
coletto et al. 2005).
Determination of LD50
The approximate median lethal dose (LD50) of A. 
amoreuxi venom was estimated using a limited number 
of experimental animals. Briefly, eight weighted mice 
were treated with IP injection with different doses (D) of 
scorpion venom. Then, the animals were monitored for 
24 h and the survival time (T) was recorded in each case. 
The regression line was generated using the data of D/T 
versus D and LD50 was calculated following the equations 
described in Meier and Theakston (1986). The approxi-




The in vitro cytotoxic effect of scorpion venom was con-
ducted using MCF-7 cell line. Cell survival was deter-
mined using sulphorhodamine B (SRB, Biotium, USA) 
method as previously described (Skehan et  al. 1990). 
Cells were seeded in 96 well microtiter plates at a con-
centration of 1000–2000 cells/well, 100  μl/well. After 
24 h, cells were incubated for 24, 48 and 72 h with various 
concentrations of A. amoreuxi venom (0, 0.01, 0.1, 1, 10, 
100 μg/ml). After 72 h from venom application, cells were 
fixed with 10 % trichloroacetic acid (150 μl/well for 1 h at 
4  °C). Cells washed three times using water and stained 
for 10–30 min at room temperature with 0.4 % SRB dis-
solved in 1  % acetic acid (70  μl/well). The unbounded 
dye was removed with 1  % acetic acid. The plates were 
air dried for 24  h, the dye was solubilized with 10  mM 
tris base of (pH 7.4, 150 μl/well) for 5 min on a shaker at 
1600 rpm. The optical density (OD) was measured spec-
trophotometrically at 540  nm using the Bio-Rad ELISA 
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microplate reader (Model 550, Japan). The value of IC50 
was calculated using sigmoidal concentration response 
curve fitting models (Sigma plot software).
DNA extraction and fragmentation analysis
DNA was extracted from both control and treated 
MCF-7 cells and fragmentation assay was performed 
(Giri et  al. 2003, Peitsch et  al. 1993). Cells were lysed 
using 10  % sodium dodecyl sulfate (SDS) for 30  min. 
Potassium acetate (8  M) was added to the supernatant 
and incubated for 1 h at 4 °C. After spinning at 7000 rpm, 
an equal volume of distilled phenol, chloroform and isoa-
myl alcohol (25:24:1) mixture was added. The mixture 
was subjected to centrifugation for 30 min at 3000 rpm, 
20 µl/ml of RNase was added and incubated for 30 min 
at 37 °C. Two volumes of chilled ethanol was added and 
allowed to stand at 20  °C overnight. The solution was 
centrifuged (10,000  rpm for 1  h at 4  °C) and the pellet 
obtained was dissolved in Tris–EDTA (TE) buffer. DNA 
was estimated by recording the absorbance at 260  nm 
and 280  nm. DNA was electrophoresed on 2  % agarose 
gel at 50 V using Tris–borate–EDTA (TBE) buffer. DNA 
was visualized by incorporation of ethidium bromide 
(1 mg/ml) in the gel during casting and viewed under UV 
illumination (302  nm). Documentation was done using 
BIO-DOC IT™ system.
In vivo experiments
Ehrlich ascites carcinoma model and animal groups
In order to examine in  vivo anticancer efficacy of scor-
pion venom, 80 female albino mice were inoculated with 
i.p. injection of 106 EAC cells in a volume of 0.2 ml. These 
mice were randomly divided into five groups (10 or 20 
mice/group). After 48 h of tumor inoculation, mice were 
treated i.p. with A. amoreuxi venom or cisplatin every 
other day according to the following scheme: Group I: 
normal mice saline-control group (normal control): ten 
normal mice were injected i.p. with 0.2  ml physiologi-
cal saline (0.9 g/dL) every other day for 13 days. Group 
II: EAC-bearing mice control group (EAC control): 20 
EAC-bearing mice injected with 0.2  ml physiological 
saline every other day for 13 days. Group III: EAC-bear-
ing mice venom-treated group: 20 EAC-bearing mice 
treated with A. amoreuxi venom (1/5 LD50; 0.22 mg/kg) 
every other day for 13 days. Group IV: EAC-bearing mice 
cisplatin-treated group (positive control): 20 EAC-bear-
ing mice treated with cisplatin (0.25 mg/kg; Santos et al. 
2011) every other day for 13 days. Group V: A. amoreuxi 
venom-treated group: ten normal mice treated with 1/5 
LD50 (0.22 mg/kg) of A. amoreuxi venom every other day 
for 13 days. The animals with ascitic tumor were weighed 
every 3 days. Total experimental period was 25 days and 
at 14th day, 6 mice in each group were anesthetized and 
sacrificed to (1) evaluate anti-tumor activity of scorpion 
venom and (2) to conduct hematological, biochemi-
cal and histopathological assay. The remaining mice in 
Group II–Group IV (n = 14 mice/each group) were kept 
alive to estimate the mean survival time (MST) and per-
cent increase in life span (% ILS).
Collection of  ascitic fluid The ascitic fluid from con-
trol and treated groups was collected for the immediate 
determination of (1) ascites tumor volume; (2) packed 
cell volume (PCV) and (3) total count/viability of Ehrlich 
ascites tumor cells (EAT) using hemocytometer and dye-
exclusion technique, respectively (Nicol and Prasad 2006). 
Viability percentage of EAT cells was calculated according 
to the following equation: (No. of viable/No. of viable and 
dead cells) × 100.
Calculation of  MST and  percentage of  ILS, T/C 
and TIR MST of each group was monitored by record-
ing the mortality daily. The end point of experiment was 
determined by the spontaneous death of animals and MST 
was calculated according to the equation: MST = (day of 
first death + day of last death)/2. The percentage of ILS 
was calculated using equation of Nicol and Prasad (2006) 
(ILS%  =  (T  −  C)/C  ×  100), where T represents MST 
of treated animals and C represents MST of the control 
group. T/C% (treated vs. EAC control) was calculated 
as MST of treated animals/MST of control group. TIR% 
(tumor-growth inhibition rate) = (C − T)/C × 100, where 
T represents mean tumor volume of treated group and 
C represents mean tumor volume of the control group. 
According to the criteria of National Cancer Institute 
(NCI), T/C exceeding 125 % and ILS exceeding 25 % indi-
cate that the drug has a significant anti-tumor activity 
(Plowman et al. 1997).
Hematological and biochemical assays Blood was with-
drawn on day 14 by cardiac puncture method from all ani-
mal groups in tubes containing EDTA (for hematological 
assays) and without anticoagulant (for serum biochemical 
analysis) in accordance with the method of Frankenberg 
(1979). Hemoglobin (Hb) and count of white blood cells 
(WBCs), red blood cells (RBCs) and differential leuko-
cyte were analyzed using standard automated procedures. 
Biochemical parameters of creatinine, aspartate ami-
notransferase (AST) and alkaline phosphatase (ALP) were 
measured in serum using commercial kits (Biodiagnostic 
Company for Laboratory Services). The levels of liver (see 
“Tissue collection and histopathological examination” 
section) glutathione (GSH, non-enzymatic antioxidant), 
malondialdehyde (MDA, end product of lipid peroxida-
tion) and protein carbonyl content (PCC, a marker of 
protein oxidation) were determined according to Beutler 
Page 4 of 12Salem et al. SpringerPlus  (2016) 5:570 
et al. (1963), Ohkawa et al. (1979) and Levine et al. (1994), 
respectively.
Tissue collection and  histopathological examina-
tion Liver and kidney were immediately excised after 
animal decapitation and rinsed in saline. Small portions 
from liver and kidney were preserved in 10 % neutral buff-
ered formalin for histopathological examinations accord-
ing to Bancroft et al. (1996). Hematoxylin and eosin (H&E) 
stained sections were examined by a light microscope and 
photographed. The rest of liver tissues were homogenized 
for biochemical analysis.
Ehrlich solid tumor model
Forty female albino mice were randomly divided into four 
groups (ten mice/group), Group I was kept as control 
while solid tumor was induced in the other three groups 
(Group II, III and IV) by subcutaneous (s.c.) inoculation 
of 0.2 ml of EAT cells (1 × 106 cells/mouse) into the thigh 
of the lower limb (Mohamed et al. 2003). After 1 week of 
tumor inoculation, mice were intraperitoneally treated 
with A. amoreuxi venom or cisplatin every other day 
according to the following scheme. Group II: ten tum-
orized mice injected with 0.2 ml of PBS every other day 
for 30 days. Group III: ten tumorized mice treated with 
1/5 LD50 A. amoreuxi venom (0.22  mg/kg) every other 
day for 30  days. Group IV: (positive control) ten tum-
orized mice treated with cisplatin (0.25  mg/kg, Santos 
et al. 2011) every other day for 30 days. Tumor mass was 
measured from the 5th day of tumor inoculation. The 
measurement was carried out every 5  days for a period 
of 30 days. The volume of solid tumor was gauged using 
Vernier caliper (after shaving the tumor bearing thigh 
of each animal) and was calculated using the formula 
of A × B2 × 0.5, where A and B are the longest and the 
shortest diameter of tumor, respectively (Orsolic et  al. 
2006). Five mice from each group were sacrificed on day 
31 and tumor mass was removed, weighed, tabulated and 
preserved in buffered formalin and processed for immu-
nohistochemical (IHC) investigations of the tumor mark-
ers KI67, caspase3 and VEGF (markers of proliferation, 
apoptosis and angiogenesis, respectively).
Immunohistochemical analysis of  solid tumors Ehrlich 
solid tumors were harvested, fixed in formalin and paraffin 
embedded for IHC analysis (Jakob et al. 2008). After anti-
gen retrieval with 10 mM sodium citrate buffer (pH 6.0) 
at 80 °C for 10 min, endogenous peroxidases were blocked 
by 3 % hydrogen peroxide in PBS for 10 min. The slides 
were then incubated overnight with primary antibodies 
against Ki67, caspase-3 and VEGF at 4 °C in a humidified 
chamber and then incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibodies at 1:100 dilutions 
for 30 min at 37 °C and visualized by 3,3′-diaminobenzi-
dine tetra hydrochloride reagent (Broad spectrum LAB-
SA Detection System from Invitrogen Cat. No. 95-9943-
B). The sections were counterstained with hematoxylin 
and digitally imaged. For IHC quantification, one thou-
sand cells from at least four separate tissue sections were 
counted (no. of animals per group = 3) using image J soft-
ware (version 1.48, 32 bit). The number of positive brown-
stained cells over the total number of cells was estimated 
and used to determine the percentage (%) of staining area 
for each tumor marker.
Statistical analysis
Statistical analysis of data was evaluated by one-way 
ANOVA followed by Tukey–Kramer test (for multiple 
comparison) to compare between control and treated 
groups. P values <0.05 were considered as indicative of 
significance for all comparisons made. All statistical anal-
yses were performed using Sigmaplot statistical software 
package version 11.
Results
In vitro cytotoxic effect of A. amoreuxi venom
The short-term in  vitro cytotoxicity study showed that 
the IC50 value of A. amoreuxi venom on MCF-7 cell 
line was 0.61 μg/ml. In an attempt to check whether the 
death of MCF-7 cells that occurred as a consequence 
of A. amoreuxi venom treatment was due to apoptosis, 
DNA fragmentation analysis was performed. DNA was 
extracted from both control and treated cells after 24 h. 
The data in Fig. 1 revealed that scorpion venom induced 
DNA fragmentation when compared to control cells.
Effect of A. amoreuxi venom on tumor growth and survival 
of EAC‑bearing mice
Treatment of EAC-bearing mice with 1/5 LD50 of A. 
amoreuxi venom (0.22  mg/kg) significantly reduced 
(P < 0.05) the increases in the mouse body weight, ascitic 
volume, PCV, total tumor cell counts and numbers of 
viable tumor cells in EAC-bearing mice as compared 
to non-treated animals (Table  1; Fig.  2). These results 
indicate that A. amoreuxi venom possesses significant 
anti-tumor effects which reached 16.32 %. On the other 
hand, the percentage of non-viable tumor cells (17.5 %), 
MST (19.5  days), ILS (25.8  %), the percentage of T/C 
(125.81 %), and tumor growth inhibition (TIR%, 25.41 %) 
of scorpion venom-treated mice were increased as com-
pared to control tumor-bearing mice (Table 1; Fig. 2).
Influence of A. amoreuxi venom on hematological 
and biochemical parameters of EAC‑bearing mice
The data in Tables  2 and 3 showed that treatment with 
A. amoreuxi venom ameliorated EAC-induced alteration 
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in hematological and biochemical parameters, including, 
RBCs and WBCs count, activities of AST and ALP. Treat-
ment with venom significantly decreased the elevated lev-
els of PCC (a biomarker for protein oxidation) and MDA (a 
biomarker for lipid peroxidation) and restored the level of 
GSH in EAC-bearing mice. These results were supported 
by histopathological sections of liver (Fig.  3) and kidney 
(Fig. 4), where sections of liver and kidney demonstrated 
a protective effect of A. amoreuxi venom to overcome the 
deleterious changes resulted from tumor development.
Effect of scorpion venom on solid tumor
In solid tumor, the average tumor volume in mice treated 
with A. amoreuxi venom every other day for 30 days was 
markedly (P < 0.05) decreased (1.43 ± 0.07 mm3) when 
compared to that of control mice (2.67  ±  0.26  mm3; 
Fig. 5), reaching about −46.4 %. Quantitatively the weight 
of tumor lumps extracted from mice treated with scor-
pion venom was smaller than those of control mice. In 
order to explore mode of action of A. amoreuxi venom 
on solid tumor, IHC analysis of Ki67, caspase-3 and 
VEGF expression in Ehrlich solid tumor tissues harvested 
on day 30 was evaluated. It was found that a significant 
(P < 0.05) inhibition in KI67 expression was observed in 
solid tumors from mice treated with A. amoreuxi venom 
as compared to control mice. Also, treatment with A. 
amoreuxi venom significantly enhanced the expres-
sion of the apoptotic molecule caspase-3 in tumor tis-
sues. Furthermore, scorpion venom down-regulated the 
expression of VEGF in tumor tissues, indicating that A. 
amoreuxi venom is able to inhibit process of neovascu-
larization (Fig. 6).
Discussion
The present study revealed cytotoxic/anti-tumor prop-
erties of A. amoreuxi on cancer cell lines (MCF-7) and 
on experimental animal tumor models (Ehrlich ascites 
and solid tumors). Treatment with A. amoreuxi venom 
showed anti-cancer activity both in  vitro or in  vivo set-
tings. The toxicity of the venom on cancer cells may be 
related to its capability to induce necrosis or apoptosis in 
cancer cells. Several previous studies reported necrotiz-
ing and apoptotic effects of scorpion venom peptides on 
different cancer cell lines. Almaaytah et  al. (2012) char-
acterized the cytolytic peptides AamAP1 and AamAP2 
(18 amino acids each) from the venom of North African 
scorpion A. amoreuxi. They found that the natural pep-
tides AamAP1 and AamAP2 showed moderate antipro-
liferative activity against the examined cell lines (LNCaP, 
U251, PC3 and HMEC-1). While the synthetic analog 
AamAP-S1 showed higher anticancer efficacy through 
inducing necrosis in PC3 prostate cancer cell line. The 
venom peptide Acra3 (66 amino acids) from the Turk-
ish scorpion A. crassicauda induced marked cytotoxic 
effect (IC50 value of 5 µg/ml) on mouse brain tumor cells 
(BC3H1) through both necrotic and apoptotic pathways 
(Caliskan et  al. 2013). Also, previous studies described 
Fig. 1 Genomic DNA fragmentation analysis of MCF‑7 cells after 
treatment with the scorpion venom A. amoreuxi. DNA was resolved 
on a 2 % agarose gel and visualized with ethidium bromide. Lane 
T treated cells with 0.5 µg/ml of scorpion venom for 24 h, lane C 
untreated cells (control), lane M molecular weight marker (1 kb lad‑
der)
Table 1 Effect of A. amoreuxi venom on body weight and survival time of EAC-bearing mice
Data are presented as mean ± SEM (six animals/group)
* Significant difference between EAC control and treated groups using student unpaired t test (P < 0.05)
Body weight (g) Survival time 
range (days)
MST (days) ILS (%) T/C (%) TIR (%)
1st day 12th day
EAC control 21.20 ± 2.41 31.62 ± 3.21 12–19 15.5 – – –
EAC + 1/5 LD50 A. amoreuxi venom 20.21 ± 1.84 28.77 ± 2.33 16–23 19.5 25.80* 125.81* 25.41
EAC + cisplatin (0.25 mg/kg) 21.48 ± 2.19 28.48 ± 3.76 16–25 20.5 32.25* 132.26* 23.88
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Fig. 2 Effect of A. amoreuxi venom on tumor growth (tumor cell count and viability, ascites volume and PCV) of EAC‑bearing mice. Hash symbol 
represents a significant difference between the three animal groups (EAC control, EAC + 1/5 LD50 A. amoreuxi venom and EAC + cisplatin) using 
one‑way ANOVA (P ≤ 0.05) followed by a Tukey post hoc test for multiple comparisons
Table 2 Effect of A. amoreuxi venom on hematological parameters of EAC-bearing mice
Data are presented as mean ± SEM (six animals/group)
# Significant difference between animal groups (normal control EAC control, EAC + 1/5 LD50 A. amoreuxi venom, EAC + cisplatin and 1/5 LD50 A. amoreuxi venom) 
using one-way ANOVA (P ≤ 0.05) followed by a Tukey post hoc test for multiple comparisons












Normal control 4.06 ± 0.18 6.08 ± 0.15 2.31 ± 0.29 45.06 ± 0.39 50.48 ± 0.57 3.58 ± 0.29
EAC control 2.44 ± 0.18 3.83 ± 0.16 3.23 ± 0.37 57.43 ± 0.42 38.53 ± 0.43 3.31 ± 0.15
EAC + 1/5 LD50 A. 
amoreuxi venom
3.96 ± 0.0.8 6.03 ± 0.12 1.86 ± 0.23 45.41 ± 74 50.66 ± 0.84 3.21 ± 0.16
EAC + cisplatin 
(0.25 mg/kg)
3.23 ± 0.42 5.60 ± 0.62 3.11 ± 0.10 60.73 ± 3.14 38.75 ± 2.65 3.50 ± 0.18
1/5 LD50 A. amoreuxi 
venom
4.59 ± 0.08# 6.38 ± 0.32# 2.71 ± 0.26# 44.23 ± 1.73# 51.55 ± 1.76# 3.36 ± 0.20
Table 3 Effect of A. amoreuxi venom on biochemical parameters in serum and liver of EAC-bearing mice
Data are presented as mean ± SEM (six animals/group)
# Significant difference between animal groups (normal control EAC control, EAC + 1/5 LD50 A. amoreuxi venom, EAC + cisplatin and 1/5 LD50 A. amoreuxi venom) 
using one-way ANOVA (P ≤ 0.05) followed by a Tukey post hoc test for multiple comparisons
AST ALP Creatinine GSH MDA PCC
Normal control 68.27 ± 0.91 82.74 ± 1.52 0.81 ± 0.07 711.07 ± 2.20 37.80 ± 0.40 2.26 ± 0.43
EAC control 123.82 ± 1.10 165.30 ± 1.14 1.58 ± 0.11 668.94 ± 1.51 45.47 ± 1.28 5.16 ± 0.74
EAC + 1/5 LD50 A. amoreuxi venom 85.08 ± 0.79 90.02 ± 1.30 1.54 ± 0.05 729.90 ± 1.10 32.48 ± 0.41 4.23 ± 0.61
EAC + cisplatin (0.25 mg/kg) 69.34 ± 0.86 99.20 ± 1.73 1.47 ± 0.03 750.98 ± 0.94 35.24 ± 1.01 4.90 ± 0.66
1/5 LD50 A. amoreuxi venom 77.13 ± 1.58# 135.71 ± 1.02# 1.51 ± 0.02# 702.00 ± 7.89# 35.08 ± 4.06# 3.99 ± 0.24#
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various necrotic and apoptotic manifestations following 
treatment with scorpion venoms on different cancer cell 
lines such as massive releasing of LDH, up-regulation of 
caspase-3 activity, membrane blebbing, chromatin con-
densation and DNA degradation (Li et  al. 1997; Gupta 
et al. 2007; Gomes et al. 2010; Zargan et al. 2011a, b, c). 
In this regard, our finding (DNA fragmentation in treated 
cells) may give an indication about the apoptotic potency 
of A. amoreuxi venom on MCF-7 cells. Interestingly, 
these results were further supported by enhanced expres-
sion of caspase-3 in Ehrlich solid tumor tissues following 
scorpion venom treatment.
Ascites fluid constitutes an essential nutritional source 
for tumor cells growing and development (Gupta et  al. 
2004). Our data showed that IP administration of A. 
amoreuxi venom significantly reduced the ascites (tumor 
volume), tumor cell count, and increased the percentage 
of trypan blue positive stained dead cells in tumor-bear-
ing mice. The reduction in tumor volume could be attrib-
uted to the treatment of A. amoreuxi venom (1) inhibited 
the proliferation of EAT cells; (2) enhanced apoptotic 
pathways of cancer cells and (3) direct necrotizing effect 
of scorpion venom phospholipase A2/cytolytic peptides 
(Almaaytah et  al. 2012). Consequently, A. amoreuxi 
venom treatment significantly increased MST and %ILS 
as compared to EAC control group. Life span prolonga-
tion (>25  %) is directly related to the decrease in viable 
cell count and ascitic fluid accumulation. It is well known 
that prolongation of life span is one of the important cri-
teria to evaluate potency of anticancer drugs. According 
to the criteria of National Cancer Institute, T/C exceed-
ing 125 % and ILS exceeding 25 % indicate that the drug 
has a significant anti-tumor activity (Plowman et al. 1997; 
Gupta et al. 2004; Agrawal et al. 2011).
Fig. 3 TS of liver of a normal control mice shows the normal architecture of hepatic lobule. The central vein surrounded by cords of hepatocytes. 
Between the strands of hepatocytes the narrow blood sinusoids are often seen, b EAC control mice shows hydropic degeneration of the hepato‑
cytes, loss of cell boundaries and ballooning degeneration. Some other hepatocytes showed nuclear pyknosis and karyolysis, c 1/5 LD50 of venom‑
treated EAC‑bearing mice shows the hepatic lobule that appear more or less like normal, d cisplatin‑treated EAC‑bearing mice shows the hepatic 
lobule that appear more or less like normal, some hepatocytes shows hydropic degeneration and ballooning degeneration, e 1/5 LD50 of venom, 
shows the hepatic lobule that appear more or less like normal. Notice the enlargement and hyperchromasia in the nuclei of the hepatocytes (H&E, 
scale bar 100 µm, magnification ×400)
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Myelosuppression and anemia (reduced hemoglobin) 
have been frequently observed in ascites carcinoma 
(Maseki et al. 1981). Anemia encountered in ascites car-
cinoma is mainly due to iron deficiency, either by hemo-
lytic or myelopathic conditions, which finally lead to 
reduced RBCs’ count (Sreelatha et al. 2011). In the pre-
sent study, elevated WBCs’ count, reduced hemoglobin 
and RBCs’ count were observed in EAC control mice, 
where administration of A. amoreuxi venom restored 
hemoglobin level and maintained normal values of 
RBCs and WBCs. The result of total differential leuco-
cytes count revealed that neutrophils increased within 
EAC-bearing mice might be due to the acute inflam-
matory response or stress due to proliferation of EAT 
cells (Hashem et  al. 2004). While neutrophils present 
in EAC-bearing mice treated with A. amoreuxi venom 
might be decreased as a result of immunostimulating 
effect of scorpion venom and defence of the host against 
Fig. 4 TS of the cortical tissue of the kidney of a normal control mice shows renal corpuscle and renal tubules, proximal convoluted tubules (short 
arrow) and distal convoluted tubules (long arrow). Notice the glomerulus (asterisk) and urinary space (arrowhead), b EAC control mice shows inflam‑
matory infiltration in the interstitial spaces (arrow). The renal corpuscles show congestion and hypercellularity (asterisk). The renal tubules exhibit 
almost normal structure, c 1/5 LD50 of venom treated EAC‑bearing mice shows the renal corpuscle and tubules appear near normal structure, d 
Cisplatin‑treated EAC‑bearing mice shows the renal corpuscles and tubules that appear near normal structure, e 1/5 LD50 of venom shows degen‑
eration of some renal tubules (arrow) (H&E, scale bar 100 µm, magnification ×400)
Fig. 5 Effect of A. amoreuxi venom on solid tumor volume (mm3) of 
EAC‑bearing mice. Data are presented as mean ± SEM (five animals/
group). Hash symbol represents a significant difference between the 
three animal groups (EAC control, EAC + 1/5 LD50 A. amoreuxi venom 
and EAC + cisplatin) at different time intervals (6, 12, 18, 24 and 
30 days) using one‑way ANOVA (P ≤ 0.05) followed by a Tukey post 
hoc test for multiple comparisons
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tumor cells. The reversal of hematological parameters 
indicates that this venom may possess protective action 
on the hematopoietic system without inducing myelo-
toxicity. For 14 days, A. amoreuxi venom did not exhibit 
any adverse effect (Sreelatha et  al. 2011). Regarding the 
elevated liver enzymes (ALP and AST) in EAC-bearing 
mice, lack of hepatic toxicity was observed upon treat-
ment with A. amoreuxi venom, indicating that the venom 
has a protective effect against organ dysfunction and cel-
lular injury of liver. These results were further supported 
by liver histopathology. Recently, Bekkari and Laraba-
Djebari (2015) reported the beneficial effects of A. austra-
lis venom which partially restored the hepatic alteration 
induced by the carcinogenic agent of fumonisin (FB1 
mycotoxin). Moreover, reducing extent of oxidative stress 
may explain how A. amoreuxi venom protected liver of 
treated animals from damage induced by tumor. We pro-
pose that treatment with A. amoreuxi venom decreased 
the tumor burden and consequently decrease oxidative 
stress manifested by restoring levels of MDA, PCC and 
GSH in liver cells. It was reported that reactive oxygen 
species (ROS) are probable mediators of cytotoxicity and 
their role in cancer development, metastasis, progres-
sion, and survival is well documented (Cerutti 1994; Sur 
and Ganguly 1994; Iqbal and Okada 2003; Goswami et al. 
2008; Tong et al. 2015). Interestingly, similar results were 
obtained with the venom of A. australis which signifi-
cantly decreased level of oxidative stress biomarkers in 
mice hepatic tumor (Bekkari and Laraba-Djebari 2015).
The present results also showed that the tumor weights 
and volumes of Ehrlich solid tumor were significantly 
decreased in mice-treated with A. amoreuxi venom 
according to our morphometrical and histological data. 
Some sort of shrinkage of tumors occurred, and the delay 
of tumor growth was evident. Inhibition of solid tumor 
growth by this venom might be as a consequence of cell 
cycle arrest, apoptosis and/or necrosis of tumor cells or 
it was the result of activation of immune system by scor-
pion venom. Inhibition of cell proliferation is considered 
as a basic parameter in cancer studies (Van Heusden 
et al. 1997). Uncontrolled cell cycle progression has been 
considered as a sign of cancer development, and there-
fore, is a usual target for developing potential anti-cancer 
drugs (Deep and Agarwal 2008). In this communication, 
the proliferation index was investigated through evalu-
ating the expression of Ki67 in solid tumors of control 
and venom-treated mice. The data clearly indicated 
that A. amoreuxi venom inhibited expression of Ki67 in 
Fig. 6 a Immunohistochemistry of KI67, caspase‑3 and VEGF in tumor sections. Tumorized mice were treated with A. amoreuxi venom (1/5 LD50) 
and cisplatin every other day for 30 days then sacrificed and solid tumor was excised to processed for IHC studies. Randomly selected areas from 
each tumor were analyzed. Arrowheads indicate immunohistochemical staining of KI67, caspase‑3 and VEGF (magnification: ×400). b Comparison 
between the stained areas of the three tumor markers KI67, caspase‑3 and VEGF using Image J
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tumor tissues as compared to control animals. Ki-67 is 
a nuclear protein expressed in proliferating cells (in all 
phases of the cell cycle except G0) and serves as a good 
marker for proliferation and may be required for main-
taining cell proliferation (Schluter et  al. 1993; Miller 
et  al. 1994). Venoms from various scorpions have been 
reported to prevent propagation of different cell lines 
such as prostate cancer, human leukemia and neuroblas-
toma (Gupta et al. 2007; Zhang et al. 2009; Zargan et al. 
2011a). For example, venom of A. crassicauda inhibited 
proliferation of human neuroblastoma cell lines through 
arresting S-phase and induction of apoptosis (Zargan 
et al. 2011a). Apoptosis is an important pathway in anti-
tumor drug response (Makin and Dive 2001; Galeano 
et al. 2005). Two pathways have been described for cells 
undergoing apoptosis; (1) death-receptor-induced apop-
tosis (extrinsic pathway through activation caspases-8, 
10 and (2) mitochondria-mediated apoptosis (intrin-
sic pathway through activation of caspases-9) (Hu and 
Kavanagh 2003; Franco et  al. 2009). Caspase-3 is a key 
protease necessary for the execution of apoptosis via the 
activation of caspases-8 leading to DNA damage and cell 
death (Zargan et  al. 2011a). The venom of A. amoreuxi 
enhanced expression of caspase-3 in solid tumor tissues 
as compared to their control group. This finding was con-
comitant with our in vitro study and may explain mecha-
nism of DNA fragmentation in MCF-7 cells treated with 
A. amoreuxi venom. Furthermore, A. amoreuxi venom 
revealed anti-angiogenic activity through down-regula-
tion the expression of VEGF in solid tumor. Inhibition of 
VEGF in tumor is an attractive strategy used to impact 
angiogenesis-dependent tumor growth and metastasis. 
Increased VEGF expression is closely associated with 
an increase in microvessel density (Sadick et  al. 2005). 
Indeed, there are few studies reported capability of scor-
pion venom peptides to suppress neovascularization and 
angiogenesis in tumor tissues through decreasing the 
level of angiogenic factors such as VIII, alpha-SMA, Dll4, 
Notch1 and VEGF (Lima e Silva et  al. 2010; Sun et  al. 
2011).
Concluding remarks
Androctonus amoreuxi venom exerted cytotoxic effects 
on tumor cells via anti-proliferative, apoptotic and anti-
angiogenic activities. Using recent technologies of ven-
omics (venom proteomics and transcriptomics), further 
studies are needed towards characterization of the active 
components from this venom (and other scorpion spe-
cies inhabiting the Egyptian deserts) and developing 
them into potential anticancer agents. Moreover, the 
present study opens the door for detailed investigations 
about interaction of scorpion venom and conventional 
antitumor drugs such as cisplatin and others.
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